Knowledge Center
Article / Oct 01, 2012
New Technologies in Particle Design. Interview: Colin Minchom, VP, Particle Design Business Unit
Source:
Drug Development and Delivery, October 2012
“An issue for customers with a poorly soluble molecule is that any one solubility enhancement technology is likely to have, I believe, a 20% to 40% probability of solving the problem. This means that in order to assure acceptable bioavailability, at least three technologies need to be investigated. The customer would need to contract with three single platform technology companies or be able to engage a single company, such as Hovione, that can apply multiple platforms, to increase the probability of solving the problem, and deliver the desired outcome.”
Related links
Also in the Knowledge Center
/ Oct 19, 2026
A dimensionless framework for hold-up mass prediction and scale transfer in continuous linear blending
Read more
Scientific Article
/ Oct 26, 2026
Streamlined development of continuous blending through integrated process understanding and predictive modeling
Read more
Scientific Article
/ Aug 04, 2026
Hovione: Accelerating Oral Drug Development Through Rapid Prototyping and Integrated Development Strategies
Read more
Scientific Article